Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Armata Pharmaceuticals Inc ARMP

Healthcare Biotechnology
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical... see more

Recent & Breaking News (NYSEAM:ARMP)

Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update

PR Newswire November 12, 2019

Armata Pharmaceuticals Issues Letter to Shareholders

PR Newswire October 31, 2019

Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive

PR Newswire October 21, 2019

Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.

PR Newswire October 10, 2019

Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference

PR Newswire September 19, 2019

Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa

PR Newswire September 12, 2019

Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update

PR Newswire August 14, 2019

Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference

PR Newswire August 1, 2019

Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York

PR Newswire June 18, 2019

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada

PR Newswire June 3, 2019

Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

PR Newswire May 28, 2019

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

PR Newswire May 9, 2019